MET should be offered as a treatment for patients with distal ureteral calculi who are amenable to awaiting management. Benefits associated with MET are a shorter time to stone expulsion and less need for analgesic drugs and hospitalization for treatment. MET is cost effective for the management of distal ureteral stones.
The primary findings show a small overall benefit for a-blockers as MET for ureteric stones but no benefit with CCBs. a-blockers show a greater benefit for large (>5 mm) ureteric stones and those located in the distal ureter, but no benefit for smaller or more proximal stones. a-blockers are associated with a greater risk of side-effects compared to placebo or CCBs. 2017 Production and hosting by Elsevier B.V. on behalf of Arab Association of Urology. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
